First-Line Immun-Checkpoint-Inhibitor-Therapy: Real World Data – Relevance of M0 versus M1 situation

C Plettenberg,Bálint Tamaskovics, Jörg Schipper,Kathrin Scheckenbach

Laryngo-rhino-otologie（2023）

引用 0|浏览0

暂无评分

摘要

Introduction Immune checkpoint inhibitors (ICI) have been shown to be effective in recurrent/metastatic head and neck cancer (rmHNSCC),. Here, the impact of the indication of recurrence and/or metastasis remains unclear. To investigate the relevance of M0/M1 status on the response of rmHNSCC to ICI in first-line therapy, we retrospectively analyzed patients with rmHNC who received checkpoint inhibitors.

查看译文

关键词

m1 situation,m0,first-line,immun-checkpoint-inhibitor-therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要